Semaglutide, the active ingredient in Ozempic and Wegovy, may do more than relieve knee osteoarthritis pain in people with obesity. It may also protect and restore damaged cartilage through a metabolic pathway that works independently of weight loss. A preclinical study published in Cell Metabolism on February 9, 2026, found that the drug reduced cartilage degeneration, osteophyte formation, and synovial lesions in an obesity-linked osteoarthritis mouse model, while a separate 68-week clinical trial of 407 adults had already demonstrated meaningful symptom improvements in humans.
Mouse Study Points to Cartilage Protection Beyond Weight Loss
The central finding driving the “reversal” claim comes from a preclinical study that tested semaglutide in mice with obesity-associated osteoarthritis. In this model, the drug showed clear chondroprotective activity, reducing cartilage degeneration, osteophyte growth, and synovial lesions while also improving pain sensitivity. Those results alone would be noteworthy, but the study went further: it identified a mechanistic pathway involving GLP-1 receptor signaling that appears to restore metabolic function in joint tissue. That distinction matters because it separates semaglutide from treatments that simply reduce mechanical load on the knee by helping patients lose weight.
The work, published in the journal Cell Metabolism and accessible via its digital object identifier, explicitly reported that semaglutide protected cartilage independent of its weight-lowering effect. The researchers framed metabolic disorders as a major contributor to the occurrence and progression of osteoarthritis, then demonstrated that correcting those metabolic disruptions at the cellular level could slow or partially reverse joint damage. In their mouse experiments, semaglutide normalized energy metabolism within chondrocytes, reduced inflammatory signaling, and limited structural deterioration even when body weight did not change substantially. If this mechanism translates to humans, it would represent a fundamentally different treatment approach for a condition that currently has no approved disease-modifying drug. Osteoarthritis care today relies almost entirely on pain management, lifestyle measures, and, eventually, joint replacement surgery when conservative options fail.
STEP 9 Trial Showed Real Symptom Relief in Humans
The preclinical findings did not emerge in a vacuum. They build on human evidence from the STEP 9 trial, a randomized, double-blind, placebo-controlled study published in the New England Journal of Medicine in October 2024. That trial enrolled 407 adults with obesity and knee osteoarthritis and followed them for 68 weeks, with participants receiving 2.4 mg of semaglutide weekly or placebo alongside lifestyle counseling. According to the investigators’ primary publication, semaglutide produced clinically meaningful improvements in pain and physical function scores, and more than 70% of people in the treatment group achieved substantial symptom relief compared with a much smaller proportion in the placebo arm. Participants receiving semaglutide also reported less pain during a six-minute walking test and showed better performance on functional assessments.
Yet there is a gap between symptom relief and structural repair. The STEP 9 trial, registered under the identifier NCT05064735, was designed to measure patient-reported pain scores, weight loss, and functional outcomes rather than imaging-based evidence of cartilage regrowth. A news summary of the trial emphasized that the data supported semaglutide as an effective weight-loss and symptom-management therapy in knee osteoarthritis, but it did not demonstrate that the drug rebuilt joint surfaces. That is where the new mouse data fills a critical hole: it provides the first mechanistic evidence that semaglutide might actually protect and restore joint tissue, not just make damaged joints hurt less. Bridging that gap with human imaging data, through MRI, radiographs, or advanced cartilage-mapping techniques, in future trials will determine whether semaglutide can be classified as a genuine disease-modifying agent for osteoarthritis rather than solely a symptomatic treatment.
Experts Urge Caution on Cost, Rebound, and Long-Term Use
Rheumatology specialists have responded to these findings with measured optimism and a strong dose of caution. In a commentary in Nature Reviews Rheumatology, domain experts noted that while the STEP 9 results are promising, semaglutide remains primarily a weight-management pharmacotherapy rather than an established disease-modifying drug for osteoarthritis. They highlighted practical concerns about the feasibility of long-term weekly injections, the potential for gastrointestinal and other adverse effects, and the risk of symptom rebound and rapid weight regain after discontinuation. Because osteoarthritis is a chronic, often lifelong condition, any therapy that must be continued indefinitely raises questions about adherence, safety over many years, and the balance between benefits and risks.
Cost and access also loom large. The same commentary pointed out that if payers and regulators continue to classify semaglutide as an anti-obesity medication rather than as a direct osteoarthritis treatment, many patients seeking it primarily for joint disease may face substantial out-of-pocket expenses. Insurance coverage policies often separate weight-loss drugs from disease-modifying therapies, and rheumatology guidelines have not yet incorporated GLP-1 receptor agonists as standard care for osteoarthritis. Until larger, longer, and more structurally focused trials confirm disease-modifying effects, specialists are likely to recommend semaglutide mainly for patients with obesity who would benefit from weight loss anyway, with improved knee pain seen as an important but secondary advantage.
Where Semaglutide Fits in the Osteoarthritis Treatment Pipeline
Separate clinical and observational work has begun to map out how semaglutide and related GLP-1 receptor agonists might fit into the broader osteoarthritis care pipeline. Investigators in China, for example, have used the Shanghai Osteoarthritis Cohort to explore whether these agents could function as potential disease-modifying drugs. Their analyses examine structural progression on imaging, inflammatory biomarkers, and clinical outcomes among people with metabolic risk factors who receive GLP-1–based therapies compared with those who do not. Early signals suggest that targeting metabolic dysfunction might slow radiographic progression in some subgroups, but these observational data cannot yet prove causality or replace randomized trials.
Other researchers are evaluating semaglutide’s role around the time of surgery. Work from Yale School of Medicine, for instance, has assessed perioperative outcomes in diabetic patients undergoing knee replacement who used semaglutide before their procedures, stratifying results by duration of use and types of complications. These analyses indicate that better glycemic control and weight reduction may translate into fewer postoperative issues, shorter hospital stays, or improved rehabilitation, suggesting that GLP-1 receptor agonists could benefit patients at multiple stages of the disease, from early metabolic risk modification to symptom relief in moderate osteoarthritis and optimization before joint replacement. At the same time, these perioperative benefits are still tied to systemic metabolic effects, not direct proof of cartilage restoration, underscoring the need for targeted imaging and mechanistic studies in humans.
What Comes Next for “Reversing” Osteoarthritis?
Despite the excitement surrounding semaglutide, experts caution that talk of “reversing” osteoarthritis is premature. The mouse data show that GLP-1 receptor signaling can correct metabolic dysfunction in joint tissues and limit structural damage, but animal models do not always predict human outcomes. The STEP 9 trial and similar studies demonstrate robust symptom relief in people with obesity and knee osteoarthritis, yet they were not powered or designed to detect cartilage regrowth. To move from promising signals to definitive conclusions, future trials will need to incorporate high-resolution imaging, longer follow-up, and careful stratification by metabolic phenotype, baseline joint damage, and weight-loss response.
Several such studies are already in motion. The STEP 9 protocol on ClinicalTrials.gov outlines exploratory imaging and biomarker endpoints that could inform the design of next-generation trials specifically aimed at disease modification. Researchers are also considering combination strategies, pairing semaglutide with physical therapy, strength training, or other pharmacologic agents that target cartilage biology more directly. If ongoing work confirms that GLP-1–based therapies can both alleviate pain and slow or partially reverse structural damage, especially in metabolically driven osteoarthritis, they could reshape how clinicians think about joint disease in the context of systemic metabolic health. Until then, semaglutide should be viewed as a powerful tool for weight management with promising but still emerging benefits for osteoarthritis, rather than a proven cure for worn-out knees.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
